{
    "nct_id": "NCT02927301",
    "official_title": "A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer",
    "inclusion_criteria": "* Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC\n* Adequate pulmonary and cardiac function\n* Available biopsy of primary tumor with adequate samples\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease\n* Any prior therapy for lung cancer within 3 years.\n* Prior treatment with anti-PD-1 or PD-L1 therapies\n* History or risk of autoimmune disease",
    "miscellaneous_criteria": ""
}